Individual Natriuretic and Diuretic Response in Acute Heart Failure: Insights from the PUSH-AHF Pharmacologic Substudy
The employer of IEB receives speaker fees by Novartis. JMtM is supported by a Dekker grant of the Dutch Heart Foundation (2020T012) for this study and declares speaker/consulting fees to institution from Bayer, Boehringer Ingelheim, Johnson and Johnson, Moderna, Novartis, Novo Nordisk, and Roche. PvdM is supported by a grant from the European Research Council (ERC CoG 101045236, DISSECT-HF). The UMCG, which employs PvdM, received consultancy fees and/or grants from Novartis, Pharmacosmos, Vifor Pharma, Astra Zeneca, Pfizer, Pharma Nord, BridgeBio, Novo Nordisk, Daiichi Sankyo, Boehringer Ingelheim and Ionis.
Authors
- Lukas Baumhove (ORCID: https://orcid.org/0000-0002-5860-7943)
- Iris E. Beldhuis (ORCID: https://orcid.org/0000-0002-3679-168X)
- Kevin Damman (ORCID: https://orcid.org/0000-0003-0190-2228)
- Wybe Nieuwland (ORCID: https://orcid.org/0000-0003-2829-3127)
- Adriaan A. Voors
- Dirk Jan van Veldhuisen (ORCID: https://orcid.org/0000-0003-1611-7935)
- Jozine M. ter Maaten (ORCID: https://orcid.org/0000-0002-4910-9336)
- Peter van Meer (ORCID: https://orcid.org/0000-0001-6493-1697)
- Jenifer E. Coster
- Jan A. Krikken
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
Publication Details
- Journal
- Journal of Cardiac Failure
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1016/j.cardfail.2025.04.015
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Bayer
- Moderna
- Hartstichting
- Novo Nordisk
- Universitair Medisch Centrum Groningen
- Vifor Pharma
- Daiichi Sankyo Europe